HPR114 Formulary Management of Biologics in Plaque Psoriasis in Canada

Abstract

Plaque psoriasis (PsO) biologics can be categorized as old-generation (anti-tumour necrosis factor and anti-interleukin (IL) 12/23 biologics) or new-generation (IL-17 and -23 inhibitors), the latter demonstrating improved efficacy in head-to-head trials. There is also an opportunity cost paid for originator biologics after loss of exclusivity (LoE) given the delayed launches and limited uptake of biosimilars in Canada. The aims of this study were to review the current funding and exclusivity status, comparative evidence, and utilization of PsO biologics, and estimate expenditures on these drugs since LoE in Canada.